Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study has the purpose to answer how the Lipoprotein(a) (Lp(a)) level is distributed among Atherosclerotic cardiovascular disease (ASCVD) patients in Russia, and what is the connection between elevated levels of this parameter and the cardiovascular disease (CVD) risk.
This study will consist of several phases (consecutive stages):
Phase I: a cross-sectional study of Lp(a) level with ASCVD patients
Phase II:
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| ASCVD patients | Patients aged 18 and above with a history of ASCVD including peripheral arterial revascularization |
| |
| Relatives of the ASCVD patients | A first-degree relative of the ASCVD patient (patient's parents and children) with Lp(a) ≥125 nmol/L. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Atorvastatin | Drug | 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors (statins) |
|
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of patients (%) with Lp(a) ≥125 nmol/L | Percentage of patients (%) with Lp(a) ≥125 nmol/L at baseline | Baseline |
| The difference in the number of patients with cardiovascular events (%) between the groups | The difference in the number of patients (%) with new cardiovascular events between the groups of patients with elevated Lp(a) ≥125 nmol/L and Lp(a) <125 nmol/L | 24 months |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of patients (%) with at least one CVD, and ASCVD number in different subgroups stratified by Lp(a) level | Percentage of patients (%) with at least one CVD by Lp(a) level: ≤25 nmol/L, 25-75 nmol/L, 75-125 nmol/L, 125-188 nmol/L, 188-250 nmol/L, ≥250 nmol/L *CVD - Cardiovascular disease; ASCVD - Atherosclerotic cardiovascular disease | Baseline |
Not provided
Inclusion Criteria:
Written informed consent (signed and dated).
Males and females aged ≥18 years.
Presence of one of the following ASCVDs for at least 3 months within the 2 years prior to signing the informed consent to participate in this study:
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply.
Not provided
Not provided
Patients with the history of atherosclerotic cardiovascular disease (ASCVD). First-degree relatives of the ASCVD patient (patient's parents and children) with Lp(a) ≥125 nmol/L
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Novartis Pharmaceuticals | Contact | +41613241111 | novartis.email@novartis.com | |
| Novartis Pharmaceuticals | Contact |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Novartis Investigative Site | Recruiting | Chelyabinsk | 454048 | Russia | ||
| Novartis Investigative Site |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Simvastatin | Drug | 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors (statins) |
|
| Rozuvastatin | Drug | 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors (statins) |
|
| Ezetimibe | Drug | Ezetimibe |
|
| Niacin | Drug | Niacin |
|
| Ciprofibrate | Drug | Fibrates |
|
| Fenofibrate | Drug | Fibrates |
|
| Bezafibrate | Drug | Fibrates |
|
| Evolocumab | Drug | PCSK9 inhibitor |
|
| Alirocumab | Drug | PCSK9 inhibitor |
|
| Inclisiran | Drug | Small interfering RNA |
|
| Percentage of ASCVD patients (%) in accordance with the Lp(a) level | Percentage of ASCVD patients (%) by Lp(a) level: ≤25 nmol/L, 25-75 nmol/L, 75-125 nmol/L, 125-188 nmol/L, 188-250 nmol/L, ≥250 nmol/L | Baseline |
| Age of patients at the time of the first ASCVD in different subgroups in accordance with the Lp(a) level | Age of patients at the time of the first ASCVD in different subgroups by Lp(a) level: ≤25 nmol/L, 25-75 nmol/L, 75-125 nmol/L, 125-188 nmol/L, 188-250 nmol/L, ≥250 nmol/L | Baseline |
| Percentage of patients (%) with disability groups I, II, and III in different subgroups stratified by the Lp(a) level | Percentage of patients (%) with disability groups I, II, and III in different subgroups stratified by the Lp(a) level: ≤25 nmol/L, 25-75 nmol/L, 75-125 nmol/L, 125-188 nmol/L, 188-250 nmol/L, ≥250 nmol/L | Baseline |
| Age of assignment of any disability group in different subgroups by the Lp(a) level | Age of assignment of any disability group in different subgroups by the Lp(a) level: ≤25 nmol/L, 25-75 nmol/L, 75-125 nmol/L, 125-188 nmol/L, 188-250 nmol/L, ≥250 nmol/L | Baseline |
| Duration of temporary incapacity (sick leave) following the onset of CVE in different subgroups based on Lp(a) level | Duration of temporary incapacity (sick leave) following the onset of CVE (cardiovascular event) in different subgroups based on Lp(a) level: ≤25 nmol/L, 25-75 nmol/L, 75-125 nmol/L, 125-188 nmol/L, 188-250 nmol/L, ≥250 nmol/L | Baseline |
| Percentage of patients (%) without an official disability status who had to completely stop working after developing CVE in different subgroups based on Lp(a) level | Percentage of patients (%) without an official disability status who had to completely stop working after developing CVE (cardiovascular event) in different subgroups based on Lp(a) level: ≤25 nmol/L, 25-75 nmol/L, 75-125 nmol/L, 125-188 nmol/L, 188-250 nmol/L, ≥250 nmol/L | Baseline |
| Lp(a) distribution level by a ASCVD type | Percentage of patients with peripheral artery disease (PAD), ischemic stroke (IS), ischemic heart disease by the Lp(a) level* *≤25 nmol/L, 25-75 nmol/L, 75-125 nmol/L, 125-188 nmol/L, 188-250 nmol/L, ≥250 nmol/L | Baseline |
| Percentage (%) of ASCVD patients with elevated Lp(a) levels by gender and age (20-30, 31-40, 41-50, 51-60, 61-70, 71-80, 81-90 years) | Percentage (%) of ASCVD patients with elevated Lp(a) levels by gender and age (20-30, 31-40, 41-50, 51-60, 61-70, 71-80, 81-90 years) | Baseline |
| Percentage of patients (%) with hemodynamically significant coronary atherosclerosis (stenosis ≥50%) in different subgroups by the Lp(a) level | Percentage of patients (%) with hemodynamically significant coronary atherosclerosis (stenosis ≥50%) in different subgroups by the Lp(a) level ≤25 nmol/L, 25-75 nmol/L, 75-125 nmol/L, 125-188 nmol/L, 188-250 nmol/L, ≥250 nmol/L | Baseline |
| Percentage of ASCVD patients (%) with elevated Lp(a) levels in groups stratified by the number of coronary arteries with hemodynamically significant stenosis in patients with relevant available data | Percentage of ASCVD patients (%) with elevated Lp(a) levels in groups stratified by the number of coronary arteries with hemodynamically significant stenosis in patients with relevant available data | Baseline |
| Percentage (%) of ASCVD patients with an elevated Lp(a) level classified depending on the presence of multifocal atherosclerosis, ischemic heart disease, and peripheral artery disease | Percentage (%) of ASCVD patients with an elevated Lp(a) level classified depending on the presence of multifocal atherosclerosis, ischemic heart disease, and peripheral artery disease | Baseline |
| Percentage of ASCVD patients (%) with elevated Lp(a) levels classified into groups with different numbers of MI events | Percentage of ASCVD patients (%) with elevated Lp(a) levels classified into groups with different numbers of myocardial infarction (MI) events | Baseline |
| Percentage of ASCVD patients (%) with elevated Lp(a) levels classified into groups with different numbers of IS and TIA events | Percentage of ASCVD patients (%) with elevated Lp(a) levels classified into groups with different numbers of ischemic stroke (IS) and transient ischemic attack (TIA) events | Baseline |
| Percentage of ASCVD patients (%) with elevated Lp(a) levels classified into groups with different types of hospitalization (planned/emergency) | Percentage of ASCVD patients (%) with elevated Lp(a) levels classified into groups with different types of hospitalization (planned/emergency) | Baseline |
| Percentage (%) of ASCVD patients with elevated Lp(a) levels classified by the first cardiovascular event (CVE) | Percentage (%) of ASCVD patients with elevated Lp(a) levels classified by the first CVE (any of the following: myocardial infarction, ischemic stroke, transient ischemic attack, percutaneous coronary intervention, etc.) | Baseline |
| Percentage of ASCVD patients (%) with elevated Lp(a) levels by the PCI number (planned/emergency) | Percentage of ASCVD patients (%) with elevated Lp(a) levels by the percutaneous coronary intervention (PCI) number (planned/emergency) | Baseline |
| Percentage of patients (%) with the first CVE (MI or IS) (before the Screening visit) in different subgroups by the Lp(a) level | Percentage of patients (%) with the first CVE (MI or IS) (before the Screening visit) in different subgroups by the Lp(a) level ≤25 nmol/L, 25-75 nmol/L, 75-125 nmol/L, 125-188 nmol/L, 188-250 nmol/L, ≥250 nmol/L | Baseline |
| Percentage of patients (%) with several CVEs (MI or IS) (before the Screening visit) in different subgroups by the Lp(a) level | Percentage of patients (%) with several CVEs (MI or IS) (before the Screening visit) in different subgroups by the Lp(a) level ≤25 nmol/L, 25-75 nmol/L, 75-125 nmol/L, 125-188 nmol/L, 188-250 nmol/L, ≥250 nmol/L | Baseline |
| Number of recurrent CVEs in different subgroups by the Lp(a) level | Number of recurrent CVEs in different subgroups by the Lp(a) level ≤25 nmol/L, 25-75 nmol/L, 75-125 nmol/L, 125-188 nmol/L, 188-250 nmol/L, ≥250 nmol/L | Baseline |
| Percentage of patients (%) with unstable angina, manifestations of TIA, PCI, and CABG in medical history (before the Screening visit) in different subgroups by the Lp(a) level | Percentage of patients (%) with unstable angina, manifestations of transient ischemic attack (TIA), percutaneous coronary intervention (PCI), and coronary artery bypass grafting (CABG) in medical history (before the Screening visit) in different subgroups by the Lp(a) level ≤25 nmol/L, 25-75 nmol/L, 75-125 nmol/L, 125-188 nmol/L, 188-250 nmol/L, ≥250 nmol/L | Baseline |
| Percentage of patients (%) with multiple CVE, such as unstable angina, TIA, PCI, and CABG (before or after the index/screening visit), in different subgroups based on Lp(a) level | Percentage of patients (%) with multiple CVE, such as unstable angina, transient ischemic attack (TIA), percutaneous coronary intervention (PCI), and coronary artery bypass grafting (CABG) (before or after the index/screening visit), in different subgroups based on Lp(a) level ≤25 nmol/L, 25-75 nmol/L, 75-125 nmol/L, 125-188 nmol/L, 188-250 nmol/L, ≥250 nmol/L | Baseline |
| Percentage of patients (%) with severe CVE (MI, IS) (after the index/screening visit) based on the Lp(a) level in different subgroups | Percentage of patients (%) with severe CVE (MI, IS) based on the Lp(a) level ≤25 nmol/L, 25-75 nmol/L, 75-125 nmol/L, 125-188 nmol/L, 188-250 nmol/L, ≥250 nmol/L at 3, 9, 12, 18, and 24 months | 3, 9, 12, 18, and 24 months |
| Number of patients with recurrent CVEs (more than one event during the follow-up period) and the mean number of recurrent complications in the post-index visit period | Number of patients with recurrent CVEs (more than one event during the follow-up period) and the mean number of recurrent complications at 3, 9, 12, 18, and 24 months | 3, 9, 12, 18, and 24 months |
| Percentage of patients (%) with cardiovascular deaths after the index/screening visit in different subgroups by the Lp(a) level | Percentage of patients (%) with cardiovascular deaths in different subgroups by the Lp(a) level ≤25 nmol/L, 25-75 nmol/L, 75-125 nmol/L, 125-188 nmol/L, 188-250 nmol/L, ≥250 nmol/L at 3, 9, 12, 18, and 24 months | 3, 9, 12, 18, and 24 months |
| Percentage of patients who died after the index/screening visit in different subgroups by the Lp(a) level | Percentage of patients who died in different subgroups by the Lp(a) level ≤25 nmol/L, 25-75 nmol/L, 75-125 nmol/L, 125-188 nmol/L, 188-250 nmol/L, ≥250 nmol/L at 3, 9, 12, 18, and 24 months | 3, 9, 12, 18, and 24 months |
| Percentage of patients (%) who needed emergency medical care or visited a medical facility during the period following the index/screening visit in different subgroups by the Lp(a) level | Percentage of patients (%) who needed emergency medical care or visited a medical facility in different subgroups by the Lp(a) level ≤25 nmol/L, 25-75 nmol/L, 75-125 nmol/L, 125-188 nmol/L, 188-250 nmol/L, ≥250 nmol/L at 3, 9, 12, 18, and 24 months | 3, 9, 12, 18, and 24 months |
| Number of emergency visits or visits to a medical facility following the index/screening visit in various subgroups by the Lp(a) level | Number of emergency visits or visits to a medical facility in various subgroups by the Lp(a) level ≤25 nmol/L, 25-75 nmol/L, 75-125 nmol/L, 125-188 nmol/L, 188-250 nmol/L, ≥250 nmol/L at 3, 9, 12, 18, and 24 months | 3, 9, 12, 18, and 24 months |
| Percentage of ASCVD patients (%) who achieved the target LDL-C level with the current lipid-lowering therapy | Percentage of ASCVD patients (%) who achieved the target LDL-C level with the current lipid-lowering therapy | 3, 9, 12, 18, and 24 months |
| Percentage of ASCVD patients (%) receiving lipid-lowering therapy, who experienced a change in Lp(a) levels | Percentage of ASCVD patients (%) receiving lipid-lowering therapy, who experienced a change in Lp(a) levels | 3, 9, 12, 18, and 24 months |
| Number of first-degree relatives (%) of patients with Lp(a) ≥125 nmol/ | Number of first-degree relatives (%) of patients with Lp(a) ≥125 nmol/L | Baseline |
| Difference between groups in the number of relatives (%) with CVD complications during the 2-year observation period | The difference in the number of relatives (%) with new cardiovascular events between the groups of patients with elevated Lp(a) ≥125 nmol/L and Lp(a) <125 nmol/L | 24 months |
| Recruiting |
| Chelyabinsk |
| 454076 |
| Russia |
| Novartis Investigative Site | Recruiting | Kaluga | 248000 | Russia |
| Novartis Investigative Site | Recruiting | Kemerovo | 650002 | Russia |
| Novartis Investigative Site | Recruiting | Krasnoyarsk | 680022 | Russia |
| Novartis Investigative Site | Recruiting | Moscow | 119881 | Russia |
| Novartis Investigative Site | Recruiting | Moscow | 121552 | Russia |
| Novartis Investigative Site | Recruiting | Moscow | 125284 | Russia |
| Novartis Investigative Site | Recruiting | Omsk | 644024 | Russia |
| Novartis Investigative Site | Recruiting | Perm | 614002 | Russia |
| Novartis Investigative Site | Recruiting | Ryazan | 390039 | Russia |
| Novartis Investigative Site | Recruiting | Surgut | 628403 | Russia |
| Novartis Investigative Site | Recruiting | Tomsk | 634009 | Russia |
| Novartis Investigative Site | Recruiting | Tyumen | 625026 | Russia |
| Novartis Investigative Site | Recruiting | Vladimir | 600020 | Russia |
| Novartis Investigative Site | Recruiting | Vladivostok | 690000 | Russia |
| Novartis Investigative Site | Recruiting | Voronezh | 394018 | Russia |
| Novartis Investigative Site | Recruiting | Yakutsk | 677013 | Russia |
| Novartis Investigative Site | Recruiting | Yekaterinburg | 620137 | Russia |
| Novartis Investigative Site | Recruiting | Yekaterinburg | 620144 | Russia |
| ID | Term |
|---|---|
| D050197 | Atherosclerosis |
| D002318 | Cardiovascular Diseases |
| ID | Term |
|---|---|
| D001161 | Arteriosclerosis |
| D001157 | Arterial Occlusive Diseases |
| D014652 | Vascular Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000069059 | Atorvastatin |
| D019821 | Simvastatin |
| D000069438 | Ezetimibe |
| D009525 | Niacin |
| C019304 | ciprofibrate |
| D011345 | Fenofibrate |
| D001629 | Bezafibrate |
| C577155 | evolocumab |
| C571059 | alirocumab |
| C585830 | ALN-PCS |
| ID | Term |
|---|---|
| D011758 | Pyrroles |
| D001393 | Azoles |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D006538 | Heptanoic Acids |
| D005227 | Fatty Acids |
| D008055 | Lipids |
| D008148 | Lovastatin |
| D009281 | Naphthalenes |
| D011084 | Polycyclic Aromatic Hydrocarbons |
| D006841 | Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D009930 | Organic Chemicals |
| D011083 | Polycyclic Compounds |
| D001384 | Azetidines |
| D001385 | Azetines |
| D009539 | Nicotinic Acids |
| D000147 | Acids, Heterocyclic |
| D011725 | Pyridines |
| D058607 | Fibric Acids |
| D058610 | Isobutyrates |
| D002087 | Butyrates |
| D000144 | Acids, Acyclic |
| D002264 | Carboxylic Acids |
| D010647 | Phenyl Ethers |
| D004987 | Ethers |
| D001577 | Benzophenones |
| D001555 | Benzene Derivatives |
| D010636 | Phenols |
| D007659 | Ketones |
| D001549 | Benzamides |
| D000577 | Amides |
| D001565 | Benzoates |
| D000146 | Acids, Carbocyclic |
| D002723 | Chlorobenzoates |
Not provided
Not provided